IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01265901
Recruitment Status : Completed
First Posted : December 23, 2010
Last Update Posted : October 12, 2017
Information provided by (Responsible Party):
immatics Biotechnologies GmbH